Marvel Biosciences Corp (MRVL) Price & Analysis

Compare

40 Followers

MRVL Stock Chart & Stats

C$0.14

-C$0.01(-6.45%)

At close: Jan 08 4:00 PM EST

C$0.14

-C$0.01(-6.45%)

Day’s Range― - ―

52-Week RangeC$0.08 - C$0.40

Previous CloseN/A

Volume5.00K

Average Volume (3M)89.38K

Market Cap

C$8.12M

Enterprise ValueC$11.25M

Total Cash (Recent Filing)C$633.54K

Total Debt (Recent Filing)C$2.31M

Price to Earnings (P/E)―

Beta-0.12

Next Earnings

Apr 01, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding58,004,482

10 Day Avg. Volume75,294

30 Day Avg. Volume89,378

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)-2.07

Price to Sales (P/S)0.00

P/FCF Ratio-7.20

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Warrant Financing ReliefHigh exercise rates from accelerated warrants deliver concrete near-term cash inflows and extend runway, reducing immediate refinancing pressure. Structurally this lowers the urgency of dilutive capital raises over the next several months and supports ongoing R&D execution.

Modest Asset GrowthAn increase in total assets versus the prior annual figure provides a firmer base for operations and modestly improves liquidity metrics. This persistent asset accumulation, even if small, enhances operational resilience over the medium term compared with a shrinking asset base.

Transparent Cash-flow RelationshipFree cash flow tracking net loss indicates cash burn is aligned with reported losses rather than hidden by non-cash charges. That transparency improves forecasting and capital planning, enabling clearer assessment of funding needs and more disciplined resource allocation over time.

Bears Say

Pre-revenue Business ModelA pre-revenue biotech model means long lead times to commercialization and persistent reliance on external capital. Without product revenue, the company must continually access financing to sustain R&D, increasing dilution risk and making long-term viability contingent on successful clinical or development milestones.

Negative Shareholders' EquityNegative equity and liabilities exceeding assets signal a stressed capital structure that constrains strategic flexibility. This elevates refinancing and solvency risk, reduces creditor confidence, and can force dilutive financing or asset sales to restore balance sheet health over the medium term.

Sustained Cash BurnPersistent negative operating cash flow and FCF of roughly -1.07M TTM demonstrate ongoing cash burn that erodes runway. This structural cash consumption necessitates repeated capital raises, heightening dilution risk and limiting the company's ability to invest strategically without securing stable financing.

Marvel Biosciences Corp News

Marvel Biosciences Wins Key U.S. Patent for Lead Neurology Drug MB-204

Marvel Biosciences Corp ( ($TSE:MRVL) ) has shared an update. Marvel Biosciences Corp. has been granted a U.S....

22h ago

Marvel Biosciences Backs European Purine Meeting to Bolster A2A Neurology Strategy

An announcement from Marvel Biosciences Corp ( ($TSE:MRVL) ) is now available. Marvel Biosciences Corp. has been named...

15d ago

Marvel Biosciences Grants Deferred Share Units to Independent Directors

Marvel Biosciences Corp ( ($TSE:MRVL) ) has issued an announcement. Marvel Biosciences Corp. has granted 50,001 deferred share...

29d ago

Marvel Biosciences Wins NRC IRAP Support for Pediatric Liquid Form of Lead Neurodrug

Marvel Biosciences Corp ( ($TSE:MRVL) ) has issued an announcement. Marvel Biosciences Corp. has secured advisory services and...

29d ago

Marvel Biosciences Wins Key Japanese Patent for Lead Neurology Drug MB-204

Marvel Biosciences Corp ( ($TSE:MRVL) ) has provided an update. Marvel Biosciences Corp. has secured a Japanese composition-of-matter...

1M ago

Marvel Biosciences Issues Deferred Share Units to Directors

Marvel Biosciences Corp ( ($TSE:MRVL) ) just unveiled an announcement. Marvel Biosciences Corp. has announced the issuance of...

4M ago

Marvel Biosciences Accelerates Warrant Expiry Amid Strong Shareholder Confidence

Marvel Biosciences Corp ( ($TSE:MRVL) ) just unveiled an announcement. Marvel Biosciences Corp. has announced the acceleration of...

6M ago

Marvel Biosciences Secures Chinese Patent for Lead Drug Candidate MB-204

Marvel Biosciences Corp ( ($TSE:MRVL) ) has provided an announcement. Marvel Biosciences Corp. has been granted a Chinese...

7M ago

Marvel Biosciences Grants Deferred Share Units to Directors

Marvel Biosciences Corp ( ($TSE:MRVL) ) has provided an update. Marvel Biosciences Corp. has announced the grant of...

7M ago

Marvel Biosciences Completes $1 Million Private Placement to Advance Neurological Research

Marvel Biosciences Corp ( ($TSE:MRVL) ) just unveiled an announcement. Marvel Biosciences Corp. has successfully closed a non-brokered...

10M ago

MRVL FAQ

What was Marvel Biosciences Corp’s price range in the past 12 months?

Marvel Biosciences Corp lowest stock price was C$0.07 and its highest was C$0.40 in the past 12 months.

What is Marvel Biosciences Corp’s market cap?

Marvel Biosciences Corp’s market cap is C$8.12M.

When is Marvel Biosciences Corp’s upcoming earnings report date?

Marvel Biosciences Corp’s upcoming earnings report date is Apr 01, 2026 which is in 13 days.

How were Marvel Biosciences Corp’s earnings last quarter?

Currently, no data Available

Is Marvel Biosciences Corp overvalued?

According to Wall Street analysts Marvel Biosciences Corp’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Marvel Biosciences Corp pay dividends?

Marvel Biosciences Corp does not currently pay dividends.

What is Marvel Biosciences Corp’s EPS estimate?

Marvel Biosciences Corp’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Marvel Biosciences Corp have?

Marvel Biosciences Corp has 58,004,482 shares outstanding.

What happened to Marvel Biosciences Corp’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Marvel Biosciences Corp?

Currently, no hedge funds are holding shares in TSE:MRVL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Marvel Biosciences Corp

Marvel Biosciences Corp. operates as a pre-clinical stage pharmaceutical development biotechnology company. It engages in the discovery and development of synthetic derivative compounds of known drugs that inhibit the A2a adenosine receptor. The company offers Nourianz (Istradefylline, KW-6002) and MB-204 an adenosine A2A receptor antagonist. It targets neurological diseases, such as Alzheimer's disease, depression and anxiety, and non-neurological conditions of cancer; and non-alcoholic steatohepatitis. Marvel Biosciences Corp. is headquartered in Calgary, Canada.